Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9621152 | 0.98 | PKM (0.80) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL8937444 | 0.94 | PKM (0.74) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL10334481 | 0.89 | POLB (0.84) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL27473699 | 0.88 | PKM (0.65) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL15303031 | 0.87 | PKM (0.65) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL27535462 | 0.85 | POLB (0.74) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| Trocimine SCHEMBL9534 | 0.84 | POLB (0.72) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL8937386 | 0.84 | ALDH1A1 (0.73) | PKMPOLBALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL8810360 | 0.83 | ALDH1A1 (0.64) | PKMPOLBALDH1A1L3MBTL1GAA | |
| SCHEMBL14076355 | 0.83 | POLB (0.97) | PKMPOLBALDH1A1CYP1A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | claimed |
| CN-117820287-A | Magnolol derivative, and preparation method and application thereof | 中国药科大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-111057035-B | Baicalein derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2021-10-26 | — | — | CN | disclosed |
| CN-110950828-B | Baicalein or derivatives thereof, preparation method and application | 中国人民解放军第二军医大学 | 2021-08-17 | — | — | CN | disclosed |
| CN-111057035-A | Baicalein derivative and preparation method and application thereof | 中国人民解放军第二军医大学 | 2020-04-24 | — | — | CN | disclosed |
| CN-110950828-A | Baicalein or derivatives thereof, preparation method and application | 中国人民解放军第二军医大学 | 2020-04-03 | — | — | CN | disclosed |
| US-6943168-B2 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES INC. (CA) | 2005-09-13 | — | — | US | disclosed |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-30 | — | — | US | disclosed |
| WO-2004089922-A2 | CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-10-21 | — | — | WO | disclosed |
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| US-4937246-A | ABSORBED EASILY FROM INTESTINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4877875-A | ANTIAGGLOMERANTS, VASODILATORS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-10-31 | — | — | US | disclosed |
| US-4837319-A | VASODILATORS, ANTICOAGULANTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0318235-A2 | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-05-31 | — | — | EP | disclosed |
| CN-88101588-A | Preparation 1, the method for 4-disubstituted piperazines compounds | — | 1988-11-23 | — | — | CN | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0242957-A1 | 1-Substituted Alkyl-1, 2-Dihydro-2-Pyrazinone derivatives | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-10-28 | — | — | EP | disclosed |
| EP-0139627-A1 | Process for the preparation of 5,10-dihydro-1H-dibenzo [B,E] [1,4] diazepin-11-ones substituted in position 5 | ARZNEIMITTELWERK DRESDEN GmbH (DE) | 1985-05-02 | — | — | EP | disclosed |
| US-4514401-A | CARDIOTONICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044004-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | PKM 3641/4885POLB 4773/4885ALDH1A1 2967/4885 |
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | PKM 3641/4885POLB 4773/4885ALDH1A1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.